$ASTS HUGE REGULATORY BREAKTHROUGH!
AST SpaceMobile just confirmed in a new FCC filing that the Ligado L-band spectrum application is advancing to NTIA review—a critical final-stretch milestone toward full FCC approval!
Why Wall Street should pay attention:
Deutsche Bank recently upgraded $ASTS to Buy ($93 PT) and valued its spectrum rights alone at ~$19+ BILLION (covering up to 45 MHz of prime L-band spectrum across the US & Canada).
Once FCC clearance unlocks this massive asset, the market has to reprice everything else sitting on top of it:
Global Satellite Constellation: Block 2 BlueBird satellites rapidly scaling toward global commercial beta service.
Tier-1 MNO & Defense Backing: Binding agreements with AT&T, Verizon, Bell Canada, plus U.S. Space Force & defense contracts.
4 Vertical Launch Independence: Building Blacklift, its own 20-ton reusable rocket (via a $1.3B Firefly engine deal, carrying 5 BlueBirds per launch) to eliminate reliance on SpaceX!
Spectrum alone justifies the valuation—the global network, defense contracts, and proprietary rocket are pure upside. THE RERATING POTENTIAL IS ENORMOUS!
$PDSB showed serious relative strength today while the broader market bled red—and now it’s pushing higher after hours!
Could tomorrow be the day? Look at what’s quietly lining up behind this move:
Heavyweight Backing: Dr. Patrick Soon-Shiong’s NantWorks just exercised warrants for another $3.9M (on top of leading up to a $22.3M PIPE) and joined the board. Smart money is positioning early.
Major Clinical Catalysts: Advancing PDS0301 toward a pivotal Phase 3 trial in metastatic colorectal cancer, with FDA protocol submission set to unlock milestone financing.
Massive Analyst Targets: Wall Street isn't blinking—H.C. Wainwright just reiterated a $5.00 PT (+450% upside) and B. Riley sits at $4.00.
Relative strength on a red day + after-hours momentum is no accident. Load the boat or get left behind!
$PLUG introduced GenEco Scale at the exact right moment!
Delivering a fully engineered, packaged green hydrogen (GH2) power solution on less than 1 acre—in a rapid-deploy "boxcar" footprint—is a game-changer for data centers, distribution hubs, municipalities, and universities.
The closed-loop setup is seamless: 20MW GenEco produces and stores GH2 on-site, feeding directly into GenSure fuel cells for instant primary and backup power.
Pair this modular speed with new permitting laws, and Plug could soon see a wave of incoming orders. That Texas facility is far more strategic than meets the eye!
$RZLV Hyper-growth in action: Rezolve AI ($RZLV) is scaling at an extraordinary pace.
Look at the numbers from our first half of 2026:
~21x Revenue Surge: Generated $130.8M in H1 2026 revenue—skyrocketing from just $6.3M in the prior-year period (+1,976% YoY).
Rapid Enterprise Adoption: Expanded our active base to over 1,640 customers by June, proving strong market demand for our AI-powered commerce solutions.
Validated by Global Giants: Across the group, our technology is trusted by some of the world’s most iconic brands, including Target, McDonald’s, The Estée Lauder Companies, and Calvin Klein.
From $6.3M to $130.8M in twelve months—this isn't just early traction, it's full-scale enterprise execution.
$BYND Regulators, it’s time to actually do your job. Turning a blind eye to relentless, allegedly predatory short selling—while leaving retail investors and legitimate companies completely unprotected—is unacceptable. Step in and enforce fair markets!
$HTZ Breaking catalyst right on cue for this Friday!
Per a fresh WSJ exclusive, real debt restructuring moves are accelerating fast:
Lenders Organizing: Barclays has tapped Lazard and Milbank to form a cohesive bank lender group and prevent revolving loans from being dumped to distressed investors.
Restructuring Advisors In Place: Hertz has retained Latham & Watkins alongside PJT Partners to tackle its nearly $18B debt load ahead of looming maturities (including $200M due this December).
Razor-Thin Margin for Error: Coming off a fresh Moody’s liquidity downgrade and a >45% slide since September down to $1.23, the clock is ticking.
With creditor groups mobilizing, any fresh headline today on restructuring progress—or pushback—could trigger violent swings. Expect extreme volatility in either direction today. Stay sharp!
$GRRR New revenue highs. Rapid margin expansion. Massive AI scale.
$GRRR just delivered a breakout Q3 2026—proving we aren't just talking about potential, we are executing at scale:
Record Top-Line Growth: Q3 revenue hit US$69.5M (+163% YoY, +39% QoQ), smashing the upper end of our guidance range by 39%.
Sharp Profitability Turnaround: Gross profit surged by US$11M sequentially, driving gross margin up 17 percentage points to 12.8%.
Heavy AI Infrastructure Buildout: Deployed ~US$218M into property and equipment in Q3 alone to power our next phase of AI compute and data center expansion.
Clear Multi-Year Trajectory: Reaffirmed our FY2026 outlook of at least US$200M alongside our ambitious US$450M–US$500M revenue target for 2027.
We are turning massive infrastructure investments into productive capacity, capacity into sustainable cash generation, and scale into lasting shareholder value.
We aren't waiting for the future of AI infrastructure—we're building it.
$OUST & Market Liquidity Watch: Anthropic just priced its massive IPO—selling all 980 million shares at $83.00 each to raise $81.34 billion, with underwriters holding an over-allotment option for another 147 million shares through Nov 20, 2026.
A capital raise of this sheer scale acts like a liquidity vacuum, pulling massive institutional dollars away from other tech and mid-cap names like $OUST. Worth checking out Tom Lee’s breakdown on the broader market ripple effects and capital rotation implications here. Very intriguing setup.
$CAPR: A Data-Driven Tug-of-War on the Eve of a Showdown—Surging Put Options vs. Nearly 4x Upside Potential!
Understanding these three key data points reveals just how conflicted Wall Street is right now:
Bearish Earnings: A quarterly loss of $0.73 per share (vs. an expected loss of $0.44)—with a cash burn rate exceeding forecasts—pushed the stock down 3.1% to $7.78.
Hedging Activity: Traders snapped up 27,192 put options in a single day—a 137% surge! Big money is scrambling for "insurance" against a potential "black swan" event.
Extreme Divergence: Analyst ratings are sharply split (5 Buys / 5 Holds / 1 Sell), yet the average price target sits at $30.09—implying nearly 4x upside from the current price!
Caught between short-term earnings pressure and a heavy buildup of bearish positions on one side, and the tantalizing prospect of a massive valuation rebound following potential regulatory approval on the other—which side are you on: the bulls or the bears?
$BULL The Bull Case on a Bear Day: The market is grossly underestimating superintelligence.
Here are the 3 massive catalysts ahead:
1% 90% Adoption
In 2 years, 90% of knowledge workers will use AI 6+ hrs/day, burning 3x the tokens/hr. Compute & API demand is about to explode.
10x Revenue Per Employee
Deploying dozens of relentless AI agents compounds output far beyond PCs or the internet—skyrocketing revenue/employee from $500K-$1M to $3M-$10M.
1,000x Personal Leverage
Ambitious builders are becoming Professor X with Cerebro, commanding an army of superhuman agents to manifest their vision in 3 years.
If you aren't using AI 5+ hrs a day, this sounds crazy. If you are, it’s obvious.
Given how severely wafer and component availability are bottlenecked, $POET’s combination of ~$750M in cash and pre-secured wafer capacity is a major differentiator. While many competing photonic startups will inevitably stall due to input shortages, $POET is positioned to execute. Increasingly, it looks like Lumilens partnered with $POET for far more than its core technology—gaining access to manufacturing infrastructure and supply allocations that would be exceptionally difficult to secure independently in this environment.
A dedicated WhatsApp group for $POET holders is now online!
All investors holding $POET stock are welcome to join this exclusive group to discuss the stock and get the latest information.
Click this link to join:stockswhatsapp.app/Uflq89
8
Currently holding $SOUN at a $6.83 average while keeping cash on the sidelines for a higher-conviction entry. Parkev makes a compelling case for a $2 valuation, and given how accurate his cautious calls have been on other names, it’s a scenario worth respecting.
Should $SOUN pull back to $2, I plan to scale in heavily to lower my cost basis—with a longer-term view that the stock reclaims double digits by the end of 2027. Strictly a long-term hold.
A dedicated WhatsApp group for $SOUN holders is now online!
All investors holding $SOUN stock are welcome to join this exclusive group to discuss the stock and get the latest information.
Click this link to join:stockswhatsapp.app/Uflq89
8
$NUAI is flashing serious bullish signals—both on the tape and fundamentally:
• Options Surge: Volume ran nearly 3x its 20-day average yesterday.
• Tightening Float: Shares available to borrow on IBKR dropped from 750K down to 250K this morning.
• Real Tenant Commitment: Most notably, the CFO revealed that the prospective tenant is already helping source equipment for the Texas site.
The Catalyst: A signed Phase 1 lease. When a tenant is already lining up hardware, paperwork usually isn't far behind.
3
13
977
A dedicated WhatsApp group for $NUAI holders is now online!
All investors holding $NUAI stock are welcome to join this exclusive group to discuss the stock and get the latest information.
Click this link to join:stockswhatsapp.app/Uflq89
7
Let’s set the record straight on $CAPR:
Capricor Therapeutics has NOT done a reverse stock split in 2026. That 52-week high wasn’t manufactured by some BS financial engineering—it was real buying, real catalysts, and real shareholders doing their thing.
Organic strength got us there once. Let’s run it back and take it there again.
2
2
692
A dedicated WhatsApp group for $CAPR holders is now online!
All investors holding $CAPR stock are welcome to join this exclusive group to discuss the stock and get the latest information.
Click this link to join:stockswhatsapp.app/Uflq89
8
$DGXX is quietly executing one of the sharpest AI infrastructure pivots in small-cap tech:
Fresh off its Q3 report, look at the numbers:
• Total Revenue: Jumped 85% QoQ (and +50% YoY) to $12.25M, returning to GAAP profitability
• AI Revenue: Exploded 400%+ QoQ to $5.66M—now nearly half of total sales
• $1.07B Anchor Deal: Signed a 10-year take-or-pay colocation contract with AI chipmaker Cerebras at its Alabama facility (~$402M Phase 1, up to $1.07B total)
• Fortress Balance Sheet: $119.6M in cash & digital assets with ZERO debt, plus 85%–90% margins on its new NeoCloudz Token Factory inference platform [1, 2, 3, 4, 5]
Trading around a ~$265M market cap while sitting on $119.6M cash and a $1B+ contracted pipeline. Hard to ignore.
A dedicated WhatsApp group for $DGXX holders is now online!
All investors holding $DGXX stock are welcome to join this exclusive group to discuss the stock and get the latest information.
Click this link to join:stockswhatsapp.app/Uflq89
6
$NWBO A notable regulatory development out of the UK for $NWBO shareholders:
The MHRA has announced a new initiative offering earlier practical regulatory support for innovative manufacturing models—specifically highlighting “personalised treatments made at or near hospitals and clinics” to accelerate patient access.
Given the pioneering, decentralized nature of DCVax-L manufacturing, it’s easy to see how NWBO’s protracted review process helped pave the way for this framework. Furthermore, with NWBO Strategic Adviser Dr. Annalisa Jenkins actively engaging alongside top MHRA leadership, $NWBO is well-positioned within the UK’s evolving regulatory ecosystem.
A dedicated WhatsApp group for $NWBO holders is now online!
All investors holding $NWBO stock are welcome to join this exclusive group to discuss the stock and get the latest information.
Click this link to join:stockswhatsapp.app/Uflq89
4
$TE HUGE catalyst for U.S. Solar in 2 weeks: Section 232 minimum import prices + 15% tariffs officially take effect Dec 4, 2026.
A dedicated WhatsApp group for $TE holders is now online!
All investors holding $TE stock are welcome to join this exclusive group to discuss the stock and get the latest information.
Click this link to join:stockswhatsapp.app/Uflq89
7
$HELP -JUST IN: Guggenheim raises its price target on $HELP (Helus Pharma) to $49 from $45 and reiterates its Buy rating following positive Phase 3 trial data. 🚨
Trading around $6.80 today, that $49 PT implies 600%+ upside. Here’s what’s backing the conviction:
• Phase 3 Win: HLP003 hit primary & key secondary endpoints in Major Depressive Disorder (MDD) with rapid onset as early as Day 2 (p<0.0001).
• Wall Street Backing: Joins H.C. Wainwright ($70 PT) and TD Cowen ($62 PT) in seeing massive value.
• Strong Cash Runway: $171.1M in cash on the balance sheet. [1, 2, 3, 4]
Big disconnect between clinical progress and current market cap.
A dedicated WhatsApp group for $HELP holders is now online!
All investors holding $HELP stock are welcome to join this exclusive group to discuss the stock and get the latest information.
Click this link to join:stockswhatsapp.app/Uflq89
6
$CRML BREAKING: Kenya has selected the Frontier Minerals Consortium over $CRML’s Mrima Earth bid for the massive Mrima Hill rare-earth & niobium project. 🚨
The Winners: Reportedly includes ReElement Technologies, $AREC (American Resources), Bunker Hill Mining & Frontier Minerals LLC.
Not Over Yet: Per Reuters, $CRML’s Mrima Earth intends to formally challenge the ruling via Kenya’s procurement authorities—and Australia’s RareX also plans to contest the award over alleged irregularities.
My Take: A near-term setback for $CRML’s expansion pipeline, yes—but it changes zero about their crown jewel Tanbreez project in Greenland. Expect legal challenges to keep this complicated for a while.
1
1
646
A dedicated WhatsApp group for $CRML holders is now online!
All investors holding $CRML stock are welcome to join this exclusive group to discuss the stock and get the latest information.
Click this link to join:stockswhatsapp.app/Uflq89
5
$MSOS is sitting near ~$3.58 amid year-end tax-loss selling—but look at the real catalysts lining up right underneath the surface:
• Dec 11 Hemp Crackdown: The federal ban on intoxicating hemp-derived THC products goes into full effect next month—wiping out unregulated grey-market competitors and funneling demand back to licensed U.S. MSOs.
• Rock-Bottom Valuation: Top U.S. cannabis operators (like $TCNNF) are now trading at just ~6x EBITDA despite steady cash flow generation.
• 2027 State Expansion: Momentum is building for adult-use/medical legalization next year in key states like Pennsylvania, Wisconsin, and even Texas.
Tax-loss pressure won’t last forever. When sentiment turns on $MSOS, it moves fast.
5
4
564
A dedicated WhatsApp group for $MSOS holders is now online!
All investors holding $MSOS stock are welcome to join this exclusive group to discuss the stock and get the latest information.
Click this link to join:stockswhatsapp.app/Uflq89
9




















